News Wire

One of the tools designed to be a “fix” for medical errors isn’t working as well as it should, according to a report from the Leapfrog Group, a nonprofit organization known for rating hospitals on patient safety. Leapfrog conducted a survey of approximately 1,800 hospitals to determine how many…
Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing human immunodeficiency virus (HIV) infection. Known as the Antibody-Mediated Prevention (AMP) studies, the trials will test whether giving people an investigational…
Researchers at the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital in Boston have designed a new type of pill that, once swallowed, can attach to the lining of the gastrointestinal (GI) tract and slowly release its contents. The tablet is engineered so that one side adheres…
The Institute for Clinical and Economic Review (ICER), a nonprofit organization whose members include drug makers and insurers, has scheduled a meeting next month to review the value of multiple myeloma treatments and to determine a benchmark for payers. The meeting comes as concerns grow over the costs…
The FDA has approved the first pacemaker that does not require the use of wired leads to provide an electrical connection between the pulse-generating device and the heart. While the Micra Transcatheter Pacing System (Medtronic) works like other pacemakers to regulate heart rate, the self-contained,…
An article published in the journal BioMetals has raised questions about the safety of the gadolinium-based contrast agents that are used in approximately 30% of magnetic resonance imaging (MRI) scans. Researchers in Israel analyzed studies detailing the known and proposed mechanisms of retained gadolinium…
Zika investigators now believe that microcephaly in newborns and Guillain–Barré syndrome in adults may be just the most obvious disorders caused by the mosquito-borne virus, according to a report from Reuters. Fueling that suspicion are recent discoveries of serious brain and spinal cord infections,…
The FDA has approved infliximab-dyyb (Inflectra, Celltrion, Inc.) for multiple indications. The product is biosimilar to infliximab (Remicade, Janssen Biotech), which was originally licensed in 1998. This is the second time the FDA has cleared a biosimilar product. Infliximab-dyyb is indicated for the…
The U.S. Preventive Services Task Force (USPSTF) has issued a final recommendation statement on screening for chronic obstructive pulmonary disease (COPD). The task force found no benefit of screening in persons without respiratory symptoms and recommends against screening for COPD in asymptomatic adults.…
Following disappointing phase 2b trial results with fispemifene in men with sexual dysfunction, California-based Apricus Biosciences has announced that it will suspend all clinical activities with the drug. Fispemifene is a once-daily orally administered selective estrogen receptor modulator (SERM)…
People with diabetes who rely on insulin have seen the cost of that drug triple in just a decade, according to a study from the University of Michigan. The increase in insulin costs was so large that, since 2010, the per-person spending on insulin has been higher than per-person spending on all other…
The FDA has given the green light to Descovy (emtricitabine 200 mg/tenofovir alafenamide 25 mg [F/TAF], Gilead Sciences), a fixed-dose combination for the treatment of human immunodeficiency virus-1 (HIV-1) infection. Descovy is indicated for use in combination with other antiretroviral agents in adults…
Staff reviewers at the FDA have supported the use of obeticholic acid (OCA, Intercept Pharmaceuticals) as monotherapy in patients with primary biliary cirrhosis (PBC) who did not respond to standard-of-care treatment. PBC results from autoimmune destruction of the bile ducts. The reviewers were unable…
Positive results have been reported from a phase 3 study investigating tofacitinib (Xeljanz, Pfizer) for the treatment of patients with psoriatic arthritis (PsA). The study evaluated the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adults with active PsA who had shown an inadequate…
Patients receiving the investigational anti-inflammatory drug losmapimod (GlaxoSmithKline) for 12 weeks after a heart attack did not show improvements in the trial’s primary endpoint, the rate of cardiovascular death, subsequent heart attack, or urgent coronary revascularization, which includes placement…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA